AVBP vs. KRRO, STOK, MLYS, ANAB, CVAC, PAHC, CALT, CMPS, OLMA, and PHAT
Should you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Korro Bio (KRRO), Stoke Therapeutics (STOK), Mineralys Therapeutics (MLYS), AnaptysBio (ANAB), CureVac (CVAC), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), COMPASS Pathways (CMPS), Olema Pharmaceuticals (OLMA), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical preparations" industry.
ArriVent BioPharma (NASDAQ:AVBP) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
ArriVent BioPharma's return on equity of 0.00% beat Korro Bio's return on equity.
9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 16.8% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ArriVent BioPharma has higher earnings, but lower revenue than Korro Bio.
In the previous week, ArriVent BioPharma had 6 more articles in the media than Korro Bio. MarketBeat recorded 8 mentions for ArriVent BioPharma and 2 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.77 beat ArriVent BioPharma's score of 0.09 indicating that Korro Bio is being referred to more favorably in the news media.
Korro Bio received 3 more outperform votes than ArriVent BioPharma when rated by MarketBeat users.
ArriVent BioPharma currently has a consensus price target of $29.25, suggesting a potential upside of 75.25%. Korro Bio has a consensus price target of $126.25, suggesting a potential upside of 107.00%. Given Korro Bio's higher possible upside, analysts plainly believe Korro Bio is more favorable than ArriVent BioPharma.
Summary
Korro Bio beats ArriVent BioPharma on 6 of the 10 factors compared between the two stocks.
Get ArriVent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ArriVent BioPharma Competitors List
Related Companies and Tools
